Production and use of Cu-67 in cancer therapy research

Cu-67的生产及其在癌症治疗研究中的应用

• 批准号: 6884914
• 负责人: HERBERT A MOORE
• 金额: $ 10万
• 依托单位: ALPHAMED, INC
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-01-10 至 2006-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6884914
• 关键词: Hodgkin' s disease; acute lymphocytic leukemia; acute myelogenous leukemia; chemical synthesis; combinatorial chemistry; copper; drug design /synthesis /production; high throughput technology; neoplasm /cancer chemotherapy; nonHodgkin' s lymphoma; zinc

DESCRIPTION (provided by applicant): The overall goal of this project is to produce large amounts of high-quality copper-67 on a routine basis, at reasonable prices to support cancer research and approved drug products. Researchers using Cu-67 have obtained promising results. Unfortunately this isotope is sporadically available and only in limited amounts when it is available and it is very expensive. Researchers are reluctant to base their work on an isotope that may not be available in quantities to support preclinical and clinical trials and approved drug products. AlphaMed's photonuclear production technology has the potential of producing large amounts of Cu-67 at reasonable costs. Commercializing this technology will result in providing researchers with a viable source of the isotope to support their preclinical and clinical trials and approved drug products. In early studies, researchers have obtained promising results with using Cu-67 in developing therapy for a number of cancers to include non-Hodgkin's lymphoma, Hodgkin's lymphoma, acute myelogenous leukemia, and acute lymphocytic leukemia. Solid tumors such as colon cancer are also being studied. Together, the incidence of these cancers is estimated by the American Cancer Society at 180,000 per year in the US and responsible for more than 80,000 deaths. Phase I of this Fast Track SBIR will demonstrate the production of Cu-67 using the photonuclear reaction on a zinc target. Then the irradiated target will be processed for the Cu-67 which will be analyzed and used for labeling studies. During Phase II the production process will be developed and demonstrated. Large amounts of high-quality Cu-67 will be produced and analyzed in pre-clinical tests. Successful conclusion of Phase II will result in a production process suitable to support clinical trials and approved drug products.

描述（由申请人提供）：该项目的总体目标是以合理的价格在常规基础上生产大量高质量的铜-67，以支持癌症研究和批准的药物产品。研究人员使用Cu-67获得了令人鼓舞的结果。不幸的是，这种同位素是零星的，只有有限的数量，当它是可用的，而且非常昂贵。研究人员不愿意将他们的工作建立在同位素的基础上，因为这种同位素可能无法大量获得，以支持临床前和临床试验以及批准的药物产品。AlphaMed的光核生产技术有潜力以合理的成本生产大量的Cu-67。这项技术的商业化将为研究人员提供一个可行的同位素来源，以支持他们的临床前和临床试验以及批准的药物产品。在早期的研究中，研究人员利用Cu-67开发了多种癌症的治疗方法，包括非霍奇金淋巴瘤、霍奇金淋巴瘤、急性髓性白血病和急性淋巴细胞白血病，取得了可喜的结果。结肠癌等实体瘤也在研究之中。据美国癌症协会估计，这些癌症在美国的发病率为每年18万例，造成8万多人死亡。快速通道SBIR的第一阶段将演示在锌靶上使用光核反应生产Cu-67。然后将辐照后的靶材加工成Cu-67，进行分析并用于标记研究。在第二阶段，生产过程将被开发和演示。将生产大量高质量的Cu-67，并在临床前试验中进行分析。II期的成功结束将导致生产过程适合支持临床试验和批准的药物产品。